Research in contextEvidence before this studyThere are few targeted agents and companion diagnostics recommended for clinical use against colorectal cancers (CRCs), despite comprehensive molecular knowledge of this cancer type. PARP inhibitors have shown clinical efficacy in various tumour types, in particular for cancers with homologous recombination deficiency (HRD), but their activity and potential molecular correlates in CRC are not well studied.Added value of this studyWe show that PARP inhibitors are effective in a subset of CRC cell lines. Existing HRD-related biomarkers with proven predictive value of PARP inhibition in other cancer types was identified in a proportion of both primary CRCs and the cancer cell cultures, but did not predict in vitro sensitivity. In contrast, pharmacogenomic analyses showed a clear association between wild-type TP53 function and PARP inhibitor sensitivity. This was consistent at different molecular levels, and both prior to treatment exposure and in response to treatment. Wild-type TP53-mediated suppression of RAD51 was identified as a possible mechanism by which PARP inhibitors exhibit their activity in pre-clinical models of CRC.Implications of all the available evidenceEmerging evidence suggests that the molecular underpinnings for efficacy of PARP inhibitors are context-dependent, and there is a need for disease-specific predictive biomarkers. We propose that wild-type TP53 activity can be involved with suppression of homologous recombination in CRC, and that *TP53* wild-type CRCs represent a relevant stratum for clinical testing of PARP inhibitors.Alt-text: Unlabelled box

1. Introduction {#sec0001}
===============

Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related deaths [@bib0001]. The therapeutic repertoire for CRC remains limited, with few targeted agents and companion diagnostics recommended for clinical use [@bib0002]. PARP inhibitors have shown clinical efficacy in molecular subgroups of diverse cancer histologies [@bib0003], [@bib0004], [@bib0005], [@bib0006]. The poly(ADP-ribose) polymerase (PARP) enzymes are key components in repair of single-stranded DNA breaks and replication fork damage [@bib0007]. PARP inhibition causes accumulation of such lesions through catalytic inhibition and trapping of PARP, eventually resulting in double-stranded DNA breaks (DSBs). Homologous recombination is the optimal pathway for accurate repair of DSBs and restarting of replication forks [@bib0007]. Accordingly, PARP inhibitors were found to be selectively active in cells with homologous recombination deficiency (HRD) due to *BRCA1* or *BRCA2* mutations \[[@bib0008],[@bib0009]\]. The demonstration of synthetic lethality between PARP inhibition and *BRCA* mutations led to clinical testing and eventually approval of olaparib as monotherapy in patients with germline *BRCA*-mutated metastatic ovarian or breast cancers \[[@bib0004], [@bib0010]\].

HRD also occurs in certain *BRCA* wild-type cancers, and further studies have identified *BRCA* wild-type tumours with sensitivity to PARP inhibitors based on three main approaches [@bib0011]. First, several DNA-based assays and signatures have been developed based on the assumption that HRD causes distinct genome-wide mutational patterns involving copy number aberrations, base substitutions and chromosomal rearrangements [@bib0012], [@bib0013], [@bib0014], [@bib0015], [@bib0016], [@bib0017]. Clinical relevance of this approach was shown by the ability of a composite HRD score [@bib0012] incorporating three different genomic instability signatures [@bib0015], [@bib0016], [@bib0017], to predict PARP inhibitor responses in ovarian and triple-negative breast cancer (TNBC) \[[@bib0003],[@bib0012]\]. Second, inactivating mutations in additional genes involved in homologous recombination, such as *ATM, ATR, CHEK1/2* and *RAD51* have also been shown to confer sensitivity to PARP inhibitors [@bib0011]. Third, gene expression-based signatures indicative of HRD and PARP inhibitor sensitivity have been developed in patient-derived material and cell lines from different cancer types, but their predictive value have not been prospectively validated in clinical material [@bib0018], [@bib0019], [@bib0020].

The role of HRD and the efficacy of PARP inhibitors have been less studied in CRC. In one phase II trial including 33 patients with metastatic CRC refractory to standard therapies, olaparib did not demonstrate any meaningful anti-tumour activity as a single-agent, but the small sample size and lack of HRD-related molecular stratification of the patients prohibit any conclusions regarding the efficacy of PARP inhibitors in CRC [@bib0021]. Notably, ATM-deficient CRC cell lines have been shown to be sensitive to PARP inhibition [@bib0022]. *ATM* and other genes critical for homologous recombination, including *BRCA1* and *BRCA2*, are somatically mutated in more than 20% of CRCs \[[@bib0011],[@bib0023]\], and germline mutations in these genes have been detected in 3% of CRCs [@bib0024]. Furthermore, pan-cancer analyses of the HRD score identified a subset of CRCs with genomic scars associated with HRD [@bib0025], while a recent study discovered elevated HRD mutational signatures in brain metastases from CRC [@bib0026]. This suggests that a significant subset of CRCs harbour genetic alterations potentially conferring sensitivity to PARP inhibitors. Furthermore, PARP1 is the main molecular target of PARP inhibitors [@bib0007] and has been shown to be overexpressed and associated with disease progression in primary CRCs and transgenic mouse models [@bib0027].

Here, we investigated mutations and genome-wide mutational patterns associated with HRD in primary CRCs, including their clinicopathological and prognostic associations. We also evaluated the activity of PARP inhibitors in a panel of 93 CRC cell lines, followed by functional analyses to identify the molecular underpinnings of sensitivity to PARP inhibition in CRC.

2. Materials and Methods {#sec0002}
========================

2.1. Patient material {#sec0003}
---------------------

A total of 255 primary tumour samples from patients operated for CRC stages I--IV at Oslo University Hospital, Norway between 2005 and 2014 were analysed. Patients in this observational study were included from a larger population-based consecutive series based on availability of whole-exome sequencing (*n* = 176) and/or DNA copy number data (*n* = 199; Supplementary Table S1). The patients were treated with standard therapies in an adjuvant or palliative setting and no patients were treated with PARP inhibitors. All participants provided informed written consent. The research conformed to the Helsinki Declaration and was approved by the Regional Committee for Medical and Health Research Ethics (REC number 1.2005.1629). The research biobanks have been registered according to national legislation.

2.2. Exome sequencing and DNA copy number analysis in primary CRCs {#sec0004}
------------------------------------------------------------------

Determination of MSI status and *TP53* mutation analysis has previously been performed \[[@bib0028],[@bib0029]\]. Matched tumour and normal colonic mucosa samples from 176 patients were subject to paired-end exome sequencing using the Agilent SureSelectXT Human All Exon V5 kit (Agilent, Santa Clara, CA, USA) and the Illumina HiSeq 2500 system (Illumina, San Diego, CA, USA) at the Oslo University Hospital Genomics Core Facility. Processing of raw sequencing reads (100 basepairs), as well as mutation calling, annotation and filtering were performed as previously described [@bib0030]. These data have partially been previously published (*n* = 33 MSI tumours) [@bib0030] or will be published elsewhere. In this study, whole-exome sequencing data were used to analyse mutations among 141 genes previously implicated in HRD [@bib0011], as described below.

DNA copy number profiles have been generated from 199 primary CRCs using Affymetrix SNP6.0 arrays (Affymetrix Inc., Santa Clara, CA, USA), and CEL files were pre-processed with PennCNV-Affy and ASCAT as previously described [@bib0031]. The fraction of the genome with aberrant copy number or loss of heterozygosity (LOH) was calculated as the percentage of aberrant bases out of the total number of bases with copy number/LOH estimates available. LOH was defined for segments in which either the A allele or B allele were zero and the remaining allele was non-zero. Complete losses were reported only for segments covered by at least 10 SNP or copy number probes.

2.3. Molecular profiles of CRC cell lines {#sec0005}
-----------------------------------------

Cell lines were obtained from American Type Culture Collection (ATCC), Cell Lines Service (CLS), DSMZ-German Collection of Microorganisms and Cell Cultures, NCI DCTD Tumour Repository, European Collection of Authenticated Cell Cultures (ECACC), JCRB Cell Bank, Korean Cell Line Bank (KCLB) and collaborators as indicated in Supplementary Table S2. Mutation data were available for 59 cell lines, either from in-house "kinome" sequencing [@bib0032] or publicly available datasets \[[@bib0033], [@bib0034], [@bib0035]\]. *TP53* mutation status was retrieved from various publications for 14 additional cell lines (Supplementary Table S2). DNA copy number (*n* = 43 cell lines) and gene expression profiles (*n* = 75 cell lines) were taken from in-house data [@bib0032] (Gene Expression Omnibus accession number GSE97023) or publicly available datasets [@bib0034] (GSE59857 [@bib0036] and GSE57083) (Supplementary Table S2). MSI status and CMS classification of cell lines was determined as previously described [@bib0037]. Cell line authenticity has been verified by short tandem repeat profiling according to the AmpFℓSTR Identifiler PCR Amplification Kit (Thermo Fisher Scientific).

2.4. Drug sensitivity screening of CRC cell lines {#sec0006}
-------------------------------------------------

Sensitivity to five PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib and veliparib) was investigated in 93 unique CRC cell lines (Supplementary Table S2) as part of an *in vitro* drug screen using a high-throughput platform including 459--529 investigational or clinically approved drugs. These data have partially been published [@bib0037] and the rest will be published elsewhere. Drug sensitivity scores (DSS) were calculated for each drug in each cell line relative to negative (mean of twelve tests with 0.1% DMSO) and positive controls (mean of twelve tests with 100 µM benzethonium chloride) based on cell viability after 72 h drug treatment at five different concentrations over a 10,000-fold concentration range (Talazoparib 0.1--1000 nM, remaining 4 PARP inhibitors at 1--10,000 nM). All dose response models were visually inspected and for spurious curves, DSS was imputed by assessing the other PARP inhibitors in the same sample (*n* = 7 out 465 values including 6 NA\'s). The overall PARP inhibitor sensitivity index for each cell line was defined as the sum of the standardized DSS (*z*-score) for four highly correlated PARP-inhibitors (see Results). Cell viability was determined using the CellTiter-Glo luminescent assay (Promega, USA).

2.5. Genomic and transcriptomic profiles associated with HRD and PARP inhibitor sensitivity {#sec0007}
-------------------------------------------------------------------------------------------

Mutations were analysed in 141 genes implicated in homologous recombination and/or PARP inhibitor sensitivity (Supplementary Table S3) [@bib0011]. Due to varying coverage in the different sources of DNA sequencing data, not all cell lines had mutation data for all relevant genes (Supplementary Table S2). A total HRD score based on DNA copy numbers was calculated using an algorithm [@bib0025] that combines three genomic scar signatures associated with HRD; number of telomeric allelic imbalances (NtAI) [@bib0017], large scale transitions (LST) [@bib0016] and HRD score (HRD-LOH) [@bib0015]. The total HRD score was calculated as the unweighted numeric sum of the three individual signatures [@bib0012].

COSMIC base substitution signatures (<https://cancer.sanger.ac.uk/cosmic/signatures_v2>) were calculated from filtered somatic single nucleotide variants in the primary CRCs tumour sample using the R package SomaticSignatures (Supplementary Methods). A gene expression signature (PARP inhibitor sensitivity score) predictive of response to PARP inhibition in preclinical models of breast and ovarian cancer [@bib0020] were calculated for the CRC cell lines (Supplementary Methods). Gene set expression enrichment analyses comparing PARP inhibitor sensitive and resistant cell lines were performed using the R package GSA and gene sets from BioCarta (collected from MSigDB: <https://www.gsea-msigdb.org/gsea/msigdb/collections.jsp>).

2.6. Drug treatment with Talazoparib, Niraparib and Pifithrin-β Hydrobromide {#sec0008}
----------------------------------------------------------------------------

The two microsatellite stable (MSS) cell lines with strongest sensitivity to PARP inhibition in the high-throughput drug screen (SKCO1 and LS513) and two resistant cell lines (SW1222 and SNU61), matched based on potentially relevant molecular features (MSS, *ATM* mutation status, consensus molecular subtype \[CMS\]), were selected for additional analyses. Among the PARP inhibitors talazoparib was chosen because it showed the greatest potency in the drug screen, but selected experiments were also performed with niraparib for validation. 2.5--4 × 10^5^ cells were seeded in 60 mm dishes (Falcon, \#353002) 24 h prior to incubation with 100 and 1000 nM talazoparib, 10000 nM niraparib (MedChemExpress, \#HY-16106), or 0.005% DMSO for control (Sigma, \#D5879) for 48 h. After the drug incubation, cells were washed twice with 1xPBS (Gibco, \#20010019) and collected after trypsinization.

Combination treatment with talazoparib and pifithrin-β hydrobromide (PFT-β) was performed for SKCO1 and LS513 in 384-well plates. Talazoparib and PFT-β as single agents or in combination were incubated for 48h and 72 h before measuring luminescence using the CellTiter-Glo luminescent assay. The effect of PFT-β on talazoparib activity was analysed with the response additivity method (additive combination drug effect predicted as the sum of the effects of single drugs), as well as combination indices using the CompuSyn 1.0 software.

2.7. Post-treatment gene expression profiling {#sec0009}
---------------------------------------------

Nucleic acids were isolated from cell pellets after treatment with talazoparib (100 nM and 1000 nM) or DMSO using the Allprep DNA/RNA/miRNA Universal Kit (Qiagen). Gene expression was analysed using the GeneChip Human Transcriptome Array 2.0 according to the manufacturer\'s instructions (Thermo Fisher Scientific, Waltham, MA, USA). Raw intensity data stored in CEL files were background corrected, quantile normalized and summarized at the gene-level according to the robust multi-array average (RMA) approach with modified Signal Space Transformation implemented in the Affymetrix Expression Console 1.1 software. The data (total *n* = 12 samples) have been deposited to GEO and can be accessed from GSE140258.

Differential gene expression analyses comparing treatment and control cultures of the two drug sensitive cell lines (SKCO1 and LS513) was performed using the R package limma (paired mode). Gene set enrichment analysis of the top differentially expressed genes (*p* \< 0.001) was performed with the R package topGO (parameters: algorithm = classic; statistic = "fisher"), based on the Gene Ontology data base and the "biological process" category. A response signature was generated based on the top 5 differentially expressed genes from limma (upregulated), and sample-wise signature scores were calculated by single-sample gene set enrichment analysis (ssGSEA function in the R package GSVA).

2.8. Western blot analysis {#sec0010}
--------------------------

Expression of TP53, P21, RAD51, β-actin; cleavage of PARP and phosphorylation of γH2A.X were analysed forty-eight hours after treatment with talazoparib, niraparib, idasanutlin or DMSO (Supplementary Methods).

2.9. Immunofluorescence and confocal microscopy {#sec0011}
-----------------------------------------------

TP53 and RAD51 nuclear expression in cell lines was analysed after 48 h treatment with talazoparib and PFT-β as described in Supplementary Methods.

2.10. Statistical analyses {#sec0012}
--------------------------

Statistical tests were performed with R (v 3.6.1) and SPSS 25.0 (SPSS Inc.) software packages. Survival curves were generated by the Kaplan-Meier method, while univariable and multivariable survival analyses were conducted according to the Cox proportional hazards model*.* In multivariable survival analyses all specified variables were entered into the models. The fraction of the genome with aberrant copy number or LOH, an indirect marker of chromosomal instability, was included as a continuous variable, while the remaining variables were categorical. Fisher\'s exact test was used to evaluate associations between categorical variables. The independent samples *t*-test or one-way ANOVA test were used, when appropriate, to compare continuous variables between groups. Correlation of drug sensitivity scores between PARP inhibitors was tested with the Pearson correlation coefficient (r), while the Spearman correlation coefficient was used to assess correlation between drug sensitivity and copy number- and gene expression-based signatures. Two-sided *p* values \< 0.05 were considered significant.

3. Results {#sec0013}
==========

3.1. Truncating mutations in homologous recombination-related genes are mutually exclusive in MSS CRC {#sec0014}
-----------------------------------------------------------------------------------------------------

Exome sequencing of 176 primary CRCs showed that all MSI tumours (*n* = 33) had multiple mutations (range 4--34) in genes implicated in homologous recombination and/or PARP inhibitor sensitivity. However, this was likely related to their hypermutated phenotype, and truncating mutations resulting from the high frequency of frameshift mutations inherent to MSI accounted for almost half (46%) of the relevant mutations ([Table 1](#tbl0001){ref-type="table"}, Supplementary Table S4). *BRCA2* and *ATM* had truncating mutations in 24% and 15% of the tumours, respectively ([Table 1](#tbl0001){ref-type="table"}), but previously published data from this cohort showed no signs of base substitution signatures associated with HRD [@bib0030] (signature 3; more or less equal representation of all base substitutions and their sequence context; [@bib0038]), as all MSI tumours had a base substitution signature dominated by defective DNA mismatch repair (signature 6).Table 1Most frequently mutated homologous recombination-related in primary CRCsTable 1MSS tumours (*n* = 143)MSI tumours (*n* = 33)GeneFrequency[1](#tb1fn1){ref-type="table-fn"} (%)Truncating[2](#tb1fn2){ref-type="table-fn"} (%)GeneFrequency (%)Truncating (%)*ATM*10 (7)3 (2)*MSH3*20 (61)20 (61)*PTEN*7 (5)1 (0.7)*ATR*16 (48)13 (39)*BRCA2*6 (4)1*BRCA2*11 (33)8 (24)*MSH3*4 (3)0*G2E3*11 (33)10 (30)*SMARCA2*3 (2)1*TOP3A*11 (33)5 (15)*REV3L*3 (2)1*REV3L*9 (27)8 (24)*SLX4*31*SMARCA2*9 (27)1 (3)*DNMT3A*30*BLM*9 (27)7 (21)*MUS81*30*TOP2B*9 (27)4 (12)*POLK*30*SHPRH*8 (24)6 (18)*C1orf86*30*ATM*8 (24)5 (15)*DNASE1L2*30*TP53BP1*7 (21)1 (3)[^2][^3]

Among the 143 MSS tumours, 74 (52%) harboured one or more mutations (range 1--5) in homologous recombination-related genes. A total of 111 mutations were detected, distributed across 59 (42%) of the 141 analysed genes. The large majority were missense mutations, while truncating (nonsense or frameshift) mutations accounted for 11% (Supplementary Table S4), were mutually exclusive, and detected in 8% of MSS tumours. *ATM* was the most frequently mutated gene (ten tumours, 7%, [Table 1](#tbl0001){ref-type="table"}) and three *ATM* mutations were predicted to be truncating, although not likely to confer complete loss of function, due to mutant allele fractions in the range of 0.21 to 0.3. One tumour harboured a frameshift mutation in *BRCA2* (p.Q1782fs), which is expected to lead to loss of BRCA2 protein function, but with a mutant allele fraction of only 0.34. None of the MSS tumours with truncating mutations in *BRCA2* or *ATM* displayed base substitution signature 3.

3.2. Various mutational patterns indicative of HRD are non-overlapping in CRC {#sec0015}
-----------------------------------------------------------------------------

Subsequently, we investigated mutational patterns associated with HRD on a DNA copy number level by calculating a previously validated HRD score [@bib0025] in 199 primary CRCs. MSS tumours had significantly higher HRD scores than MSI tumours (mean MSS 17.8 *versus* MSI 5.6, *p* \< 0.001, independent samples t-test, [Fig. 1](#fig0001){ref-type="fig"}a, Supplementary Table S5a), and the HRD scores were associated with the fraction of the genome with aberrant copy number (*r* = 0.66, *p* \< 0.001, Pearson\'s correlation). This is in line with previous results across cancer types [@bib0025] and supports that the frequent truncating mutations in homologous recombination-related genes in MSI tumours do not have a significant impact on the ongoing mutational processes.Fig. 1HRD scores and their prognostic impact in primary colorectal cancers. a DNA copy number-based HRD scores in 199 primary tumours, split according to MSI status. Dashed horizontal line marks HRD score ≥ 42 used as threshold for homologous recombination deficiency in previous non-CRC publications. b Kaplan-Meier survival curves showing five-year overall survival (OS) in patients with MSS tumours with high (above median) and low HRD scores (below median) in stage III (left panel) and stage IV (right panel).Fig 1

High HRD scores were further associated with *TP53* mutations, left sided tumour location, and stage III or IV tumours (Supplementary Table S5a). Univariable survival analysis encompassing all disease stages in MSS tumours showed that high HRD scores (above median) were associated with inferior five-year overall survival (hazard ratio (HR) 2.00; 1.16--3.44; *p* = 0.013, Supplementary Fig. 1a). Stage-specific analyses demonstrated negative prognostic impact of high HRD scores among stage III (HR 5.21; 1.19--22.82; *p* = 0.029, [Fig. 1](#fig0001){ref-type="fig"}b) and IV MSS cancers separately (HR 2.51; 1.02--6.2; *p* = 0.045, [Fig. 1](#fig0001){ref-type="fig"}b), while no association with survival was seen in stages I--II (Supplementary Fig. S1b). Stage-specific negative prognostic trends were seen also in multivariable analyses incorporating age, gender, primary tumour location, chemotherapy, *TP53* mutation status and the extent of genomic copy number aberrations, although statistically significant only in stage IV (Stage III: HR 2.98; 0.56--16.02; *p* = 0.20, Stage IV: HR 3.04; 1.02--9.09; *p* = 0.046).

Five MSS tumours (2.5%) had HRD scores ≥ 42 (Supplementary Table S5b), which has been indicative of HRD and PARP inhibitor sensitivity in other cancer types \[[@bib0003],[@bib0012]\]. Two of these five samples had whole-exome sequencing data available; one sample (HRD score 43) harboured three individual missense mutations in *RAD23B*, while the other (HRD score 46) had missense mutations in *BRCA2* and *FANCG*. However, none of the two tumours had base substitution signatures associated with HRD ([Fig. 2](#fig0002){ref-type="fig"}a). Signature 3 was the largest contributor to underlying mutational processes in three (2%) of the 143 MSS tumours ([Fig. 2](#fig0002){ref-type="fig"}b). One of these harboured a frameshift mutation in *POLQ*, with a mutant allele fraction of 0.30. The other two did not have any truncating mutations in homologous recombination-related genes. Across all MSS tumours, there was no difference in HRD scores between tumours with a detectable contribution of signature 3 (at least 5% relative contribution) compared with tumours without contribution from this signature (*p* = 0.9, independent samples *t*-test, [Fig. 2](#fig0002){ref-type="fig"}c). In summary, we identified gene-specific or genome-wide mutational patterns associated with HRD in a small subset of MSS tumours. However, there was no sample overlap between the features, and altogether non-consistent evidence of HRD in the genome of these primary CRCs.Fig. 2Base substitution mutational signatures in primary colorectal cancers. a Relative contribution of the various base substitution mutational signatures (as designated in COSMIC and described by Alexandrov *et al*.) in the two samples with HRD scores ≥ 42 and available whole-exome sequencing data. b Relative contribution of mutational signatures in the three samples where signature 3 was most dominant. One sample harboured a frameshift mutation in *POLQ* and a missense mutation in *XAB2* with mutant allele fractions of 0.30 and 0.66, respectively. Another sample had a missense mutation in C19orf40 with a mutant allele fraction of 0.21, while no mutations in homologous recombination-related genes were detected in the last sample. None of these three tumours had DNA copy number data and HRD scores available. The frequency of different types of base substitutions for [Fig. 3](#fig0003){ref-type="fig"}a and b is shown in Supplementary Fig. S2a--b. c Comparison of HRD scores in MSS tumours according to relative contribution of signature 3. *P* value from independent samples *t*-test.Fig 2

3.3. A small subset of CRC cell lines are sensitive to PARP inhibition {#sec0016}
----------------------------------------------------------------------

The *in vitro* drug screen of 93 CRC cell lines showed that PARP inhibition was active in a small subset of samples, based on the standardized and summed DSS (the PARP inhibitor sensitivity index) of four different PARP inhibitors (olaparib, niraparib, rucaparib and talazoparib; [Fig. 3](#fig0003){ref-type="fig"}a). Among the five PARP inhibitors tested, talazoparib was the most potent in the 8 most sensitive cell lines ([Fig. 3](#fig0003){ref-type="fig"}b). Veliparib was least potent and correlated weakly with the four others (Pearson\'s *r* \< 0.3, Supplementary Table S6), possibly due to its previously reported lacking ability to trap PARP [@bib0007], and was therefore removed from the analyses.Fig. 3PARP inhibitor drug sensitivity scores per cell line. a Barplot with cell lines ordered according to a PARP inhibitor sensitivity index (the sum of the standardized drug sensitivity score for four PARP inhibitors with veliparib excluded due to low activity/low correlation). Dashed horizontal line indicates value used for dichotomy in downstream analyses. Samples are coloured according to MSI-status (dark grey: MSI; grey: MSS; white: unknown). Histogram shows distribution of PARP inhibitor drug sensitivity scores among 93 cell lines. b Comparison of potency of the five PARP inhibitors based on drug sensitivity scores in the eight cell lines classified as PARP inhibitor sensitive. *P* values are from paired-samples *t*-tests.Fig 3

The target *PARP1* was highly expressed in most cell lines, and correlated weakly with sensitivity (Pearson\'s *r* = 0.23; Supplementary Fig. S3a). MSI cell lines had in general a higher PARP inhibitor sensitivity index than MSS (*p* \< 0.001, Wilcoxon rank sum test), but the three most sensitive cell lines were MSS. The cell lines were characterized as sensitive or resistant using a threshold value for the sensitivity index of 5 (defined by a discontinuity in the distribution of index values), classifying 8 of 93 cell lines (9%) as sensitive ([Fig. 3](#fig0003){ref-type="fig"}a, [Table 2](#tbl0002){ref-type="table"}). These included 4 MSS and 4 MSI cell lines. Although there was an enrichment with MSI among the sensitive cell lines (OR = 7.4; 95% confidence interval, 1.59 --34.35, *p* = 0.017, Fisher\'s exact test), the positive predictive value of MSI status for sensitivity to PARP inhibition was only 29%.Table 2Molecular characteristics of PARP inhibitor sensitive cell linesTable 2MSI status*TP53*CMSHRD scoreBiallelic aberration HR gene[1](#tb2fn1){ref-type="table-fn"}No. of mutated HR genes[2](#tb2fn2){ref-type="table-fn"}PARPi sensitivity score[3](#tb2fn3){ref-type="table-fn"}SKCO1MSSwtCMS350*ATM*1-0.37LS513MSSwtCMS39No40.06COLO205MSSmutn.a.42No1-0.16HCT116MSIwtCMS417*MSH3*320.42HROC87MSIn.a.CMS1n.a.n.a.n.a.n.a.MDST8MSSwtCMS421*PTEN, REV3L*60.1LS174TMSIwtCMS322No230.06SW48MSIwtn.a.7No230.45[^4][^5][^6]

3.4. Existing HRD-related mutations and genomic signatures have limited predictive power for PARP inhibition in CRC cell lines {#sec0017}
------------------------------------------------------------------------------------------------------------------------------

All the PARP inhibitor sensitive cell lines with available DNA sequencing data (*n* = 7) harboured mutations in at least one gene implicated in homologous recombination and/or PARP inhibitor sensitivity (range 1--32 mutated genes, [Table 2](#tbl0002){ref-type="table"}, Supplementary Table S7), although biallelic alterations were detected in only 3 cell lines (2 MSS, 1 MSI, [Table 2](#tbl0002){ref-type="table"}). SKCO1 (MSS) had a homozygous splice mutation in *ATM*, while HCT116 (MSI) and MDST8 (MSS) had homozygous mutations in *MSH3* and *PTEN*, respectively. MDST8 also harboured a hemizygous mutation in *REV3L*. None of the sensitive samples with DNA copy number data had complete losses of any of the homologous recombination-related gene loci. Notably, 31% (16/52) of the PARP inhibitor resistant cell lines also had homozygous mutations in at least one of these genes, including truncating mutations in *MSH3* (HCA7), *PTEN* (LIM2405) or *ATM* (SW1222). The positive predictive value of a homozygous mutation in any homologous recombination-related gene for PARP inhibitor sensitivity was only 16%, suggesting shortcomings in applying an HRD-related gene-specific strategy to predict PARP inhibitor sensitivity in CRC.

Next, we evaluated the predictive power of the DNA copy number based HRD score [@bib0012] and a gene expression-based signature of PARP inhibitor sensitivity [@bib0020]. Neither the genomic HRD scores (*n* = 43 cell lines; HRD scores: resistant 28.6 *versus* sensitive 24.0, *p* = 0.5, independent samples *t*-test) nor the transcriptomic sensitivity score (*n* = 75 cell lines; *p*= 0.46, independent samples *t*-test) were associated with efficacy of PARP inhibition in CRC cell lines. Both signatures lacked predictive value also when analysed separately in MSI and MSS cell lines (*p* \> 0.6). These results indicate that predictive signatures of PARP inhibitor efficacy developed in other cancer types cannot be translated to CRC.

3.5. PARP inhibitor sensitivity is strongly associated with *TP53* wild-type status in CRC cell lines {#sec0018}
-----------------------------------------------------------------------------------------------------

Further exploratory analyses of the molecular correlates of PARP inhibitor sensitivity were focused on the MSS subgroup to reduce the potential influence from DNA repair mechanisms not related to homologous recombination. Gene set expression enrichment analysis (GSEA) showed that DNA damage-, TP53-, and immune-related signatures were upregulated in sensitive compared to resistant cell lines ([Fig. 4](#fig0004){ref-type="fig"}a). Moreover, a significant enrichment with *TP53* wild-type status was seen among the PARP inhibitor sensitive samples (OR = 15.7; 95% confidence interval 1.5--168.1, *p* = 0.023, Fisher\'s exact test, [Fig. 4](#fig0004){ref-type="fig"}b). Notably, this was also evident when including MSI cell lines (*p* = 0.001; Supplementary Table S8a and Fig. S3b), and multiple regression analysis incorporating *TP53* and MSI status showed that only the former was significantly associated with PARP inhibitor sensitivity (*p* = 0.001 and *p* = 0.39, respectively, Supplementary Table S8b).Fig. 4PARP inhibitor sensitivity is associated with TP53 activity. a Gene set enrichment analysis comparing PARP inhibitor resistant (*n* = 53) and sensitive (*n* = 4) colorectal cancer cell lines. Only microsatellite stable cell lines are included. Gene sets from BioCarta. The ten most upregulated gene sets in PARP inhibitor sensitive cell lines are shown, ranked according to *p* values (log10-scale). b Barplot shows summed standardized PARP inhibitor drug sensitivity scores per cell line, ranked according to drug sensitivity and coloured according to *TP53* mutation status. Dashed horizontal line indicates value used for dichotomy in downstream analyses. Only MSS cell lines with known *TP53* mutation status are included (*n* = 60). Similar plot including MSI cell lines is shown in Supplementary Fig. S3A. c Gene set enrichment analysis of genes associated with PARP inhibitor response. Analysis based on genes upregulated (paired limma-analysis) in PARP inhibitor sensitive cell lines (SKCO1 and LS513) after treatment with talazoparib compared to DMSO (control). d Five-gene response signature (*GDF15, PLK2, MDM2, TP53INP1, RRM2B*) according to *TP53* mutation status in untreated MSS cell lines. e Comparison of PARP inhibitor sensitivity scores in MSS *TP53* wild-type (wt) cell lines split according to the 5-gene response signature. Samples are dichotomized according to high or low gene response signature using a threshold of 0.3, reflecting the largest discontinuity in the distribution of response signature values. *P* value from Welch\'s t-test.Fig 4

3.6. Transcriptional activity downstream of TP53 is a primary response to PARP inhibition in CRC cell lines {#sec0019}
-----------------------------------------------------------------------------------------------------------

Response mechanisms of PARP inhibition were analysed by gene expression profiling of pairs of sensitive (SKCO1 and LS513; *TP53* wild-type) and resistant (SW1222 and SNU61; *TP53* mutated) MSS cell lines after treatment with talazoparib or DMSO for control (Supplementary Fig. S3c-d and Table S9). GSEA of the most upregulated genes (treatment versus control) in the two sensitive cell lines showed that DNA damage repair, and more specifically TP53 activity, was among the primary response mechanisms ([Fig. 4](#fig0004){ref-type="fig"}c). Notably, the five most upregulated genes (*GDF15, PLK2, MDM2, TP53INP1, RRM2B*) were all known transcriptional targets of TP53, and were upregulated exclusively in the sensitive cell lines (Supplementary Fig. S3e). A treatment response signature based on these five genes was significantly upregulated in *TP53* wild-type compared to mutated samples in the larger panel of MSS cell lines prior to treatment exposure ([Fig. 4](#fig0004){ref-type="fig"}d). Furthermore, in the *TP53* wild-type group, sensitivity to PARP inhibitors was indeed higher in cell lines with a high response signature ([Fig. 4](#fig0004){ref-type="fig"}e), although the low number of cell lines within each subgroup precluded statistically significant associations (*p* = 0.056).

Increased transcriptional activity downstream of TP53 was further investigated at the protein level after treatment with two different PARP inhibitors (talazoparib and niraparib) and an MDM2-TP53 wild-type interaction inhibitor (idasanutlin) as a positive control ([Fig. 5](#fig0005){ref-type="fig"}a and Supplementary Fig. S4 and S5). Idasanutlin increased the protein levels of both TP53 and its downstream cyclin-dependent kinase inhibitor P21 strongest in the PARP-inhibitor sensitive and *TP53* wild-type cell lines. There was no further increase after combination with PARP inhibition, but single-agent treatment with either PARP inhibitor increased the expression levels of P21 exclusively in the sensitive cell lines. Collectively, these data suggest that PARP inhibitor sensitivity is associated with wild-type TP53 activity in CRC.Fig. 5TP53 activation and regulation of RAD51 after PARP inhibition. a Western Blot analyses of TP53, p21 and RAD51 in PARP inhibitor sensitive (SKCO1 and LS513) and resistant cell lines (SW1222 and SNU61) after treatment with talazoparib, niraparib and idasanutlin for 48 h. b Representative images of TP53 expression and RAD51 foci analysed with fluorescence microscopy after 48 h treatment with 1 µM talazoparib, 50 µM pifithrin-β (PFT-β) or combination of the two. Scale bar = 20 µm. Scatter dot plots below depict analysed TP53- (red) and RAD51 (green) mean fluorescence per nuclei for the indicated treatment and cell lines, respectively. For statistical analyses, one-way ANOVA multiple comparison test with Tukey post correction was performed (\*\*\*\**p* \< 0.0001, \*\**p* \< 0.005, \**p* \< 0.05). Each dot represents mean fluorescence in one nuclei and grey area indicates analysed nuclei (black) with no TP53 or RAD51 expression. c Viability of SKCO1 and LS513 cell lines after 72 h combination treatment with talazoparib and PFT-β. Values given are means ± standard error of the mean. Dotted lines indicate the predicted additive effect calculated as the sum of mean inhibitory effects from single drugs. Values above the bars for combination treatments indicate combination indexes (CI). CI \< 1, CI = 1 or CI \> 1 represent synergism, additive and antagonistic effects, respectively. d Schematic depiction of TP53 and RAD51 involvement after PARP inhibition in TP53 wild-type cell lines.Fig 5

3.7. Wild-type TP53 inhibits RAD51 foci formation in response to PARP inhibition {#sec0020}
--------------------------------------------------------------------------------

To evaluate the involvement of homologous recombination in the association between wild-type TP53 and sensitivity to PARP inhibition, we analysed RAD51 expression and RAD51 foci formation, which are surrogate markers of homologous recombination functionality [@bib0039]. Consistent with a previous study reporting that wild-type TP53 can repress RAD51 transcription in response to double-stranded DNA breaks (40), we observed decreased RAD51 protein expression after talazoparib treatment in the two *TP53* wild-type cell lines SKCO1 and LS513. Down-regulation of RAD51 was strongest in SKCO1, which was also the cell line most sensitive to PARP inhibition ([Fig. 5](#fig0005){ref-type="fig"}a and Supplementary Fig. S6a and S6c). Similar results were found by immunofluorescence microscopy, showing that talazoparib significantly increased the number of TP53-positive nuclei (3 fold) and decreased the RAD51 foci (3 fold) in SKCO1, and to a lesser extent in LS513 (3% increase of TP53 expression and 2% decrease of RAD51 foci; [Fig. 5](#fig0005){ref-type="fig"}b) Consequently, SKCO1 also exhibited the highest increase of the DNA double-strand break marker γH2A.X and the apoptotic marker cleaved PARP after talazoparib treatment (Supplementary Fig. S6a, d-e). In contrast to talazoparib, treatment with the TP53 inhibitor PFT-β had the opposite effect on TP53 and RAD51, with a significant decrease of TP53 expression and 4 fold decrease of expressing nuclei, as well as an increase of nuclei with RAD51 foci (4 fold) in SKCO1. A significant increase of RAD51 foci was also observed in the LS513 cell line after TP53 inhibition, despite the fact that fewer RAD51 expressing nuclei were counted compared to control (1.3 fold). Consequently, co-treatment with PFT-β and talazoparib in the two PARP inhibitor sensitive cell lines showed that TP53 inhibition antagonized the impact of PARP inhibition on cell viability after 48h and 72h, providing further support that wild-type TP53 is required for the activity of PARP inhibitors in CRC cell lines ([Fig. 5](#fig0005){ref-type="fig"}c--d and Supplementary Fig. S7).

4. Discussion {#sec0021}
=============

The clinical potential of targeting low-frequency molecular aberrations in CRC has been demonstrated using several anticancer agents with different mechanisms of action \[[@bib0041], [@bib0042], [@bib0043]\]. Our results from high-throughput drug screening of a large panel of CRC cell lines suggest a potential for development of a PARP inhibitor strategy. However, only a small subset of the cell lines was sensitive to PARP inhibition, highlighting the need to identify accurate response prediction markers. Existing transcriptomic and genomic signatures related to HRD and with proven predictive value in other cancer types had poor predictive power in CRC. In contrast, a clear association was found between wild-type TP53 function and PARP inhibitor sensitivity. This was consistent at different molecular levels and in different analysis settings, including *TP53* wild-type status, a TP53-related gene expression signature within the *TP53* wild-type group, downstream TP53 activity as one of the main response mechanisms after treatment, and the antagonistic effect of TP53 inhibition. This is somewhat in contrast to the efficacy of PARP inhibitors seen in ovarian cancer, in which *TP53* is almost invariably mutated [@bib0044]. However, recent publications have shown that synergy between PARP inhibition and either ionizing radiation or chemotherapy depends on functional TP53 \[[@bib0045],[@bib0046]\]. Furthermore, reactivation of mutant TP53 in combination with olaparib showed highly effective tumour growth inhibition in pre-clinical models of *TP53* mutant TNBC [@bib0047]. These findings indicate context-dependent molecular underpinnings for PARP inhibitor efficacy. While our study does not imply that *TP53* mutation status has sufficient predictive value to be used as a solitary biomarker for PARP inhibition in CRC, it may point to the *TP53* wild-type group as an overarching stratum more likely to contain responders. Our study is based on the in vitro activity of PARP inhibition, and additional pre-clinical analyses are needed to specify a strategy for clinical testing.

DNA damage-related mechanisms were indeed involved in responses to PARP inhibition also in CRC cell lines, but not necessarily related to the known genomic markers of HRD. In most genes implicated in homologous recombination and PARP inhibitor sensitivity, biallelic aberrations are required for oncogenic impact [@bib0011]. We identified biallelic aberrations in *ATM, PTEN* and *MSH3* in three of the PARP inhibitor sensitive cell lines. Homozygous deletion of *ATM* in SKCO1 cells (*TP53* wild-type) has been shown to induce sensitivity to olaparib [@bib0022], whereas PTEN deficiency has been shown to sensitize CRC cell lines to PARP inhibition [@bib0048]. However, the lack of PARP inhibitor sensitivity in other cells harbouring homozygous frameshift mutations in *ATM* (SW1222: *TP53* mutated) and *PTEN* (LIM2405) in our study, demonstrates a more complex biomarker-drug association. Notably, while loss of BRCA1 *or* PTEN have been shown to cause HRD in diverse cancer cells, simultaneous inactivation of both genes reactivates homologous recombination and confers resistance to PARP inhibition [@bib0018]. Thus, each mutation must be interpreted in the context of other relevant co-occurring mutations to precisely characterize the effect on homologous recombination competence and PARP inhibitor sensitivity. Our results suggest that *TP53* mutation status should be taken into account in CRC.

Analyses of response mechanisms to PARP inhibitors suggested that RAD51 may provide a link between wild-type TP53, HRD and treatment sensitivity in CRC. RAD51 is a crucial player in homologous recombination and assists in double-strand break repair by binding to DNA and mediating homologous pairing and strand exchange [@bib0049]. Up-regulation of RAD51 seems to reduce sensitivity to excessive DNA damage in cancer cells and to represent a compensatory pathway for other deficient repair mechanisms [@bib0050]. TP53 has been reported to down-regulate important homologous recombination proteins, including RAD51, and thus inhibit inappropriate DNA repair [@bib0040]. However, the frequent mutations of *TP53* in tumour cells cause a tendency for RAD51 to be overexpressed and to increase the resistance to DNA damage. Notably, a recent study in patient-derived CRC models demonstrated that RAD51 foci formation after exposure to radiation was associated with resistance to olaparib, supporting the relevance of RAD51 as a marker of homologous recombination proficiency and sensitivity to PARP inhibitors [@bib0051]. These results are in line with our findings, which indicated that wild-type TP53-mediated suppression of RAD51 is a possible mechanism by which PARP inhibitors exhibit their activity.

The limited overlap of previously reported genomic and transcriptomic signatures of HRD among primary CRCs in our study supported the pre-clinical data and indicated that the molecular characteristics of HRD are different in CRC than other cancer types in which synthetic lethality with PARP inhibition is well described. The poor-prognostic association of a high DNA copy number-based HRD score in stage III-IV CRC is supported by analyses of CRCs in TCGA [@bib0052], but is in contrast to the positive prognostic impact of HRD in TNBC and ovarian cancer \[[@bib0015],[@bib0017]\]. The latter analyses were performed in patient cohorts receiving the DNA damaging compounds cisplatin or carboplatin, to which HRD confers sensitivity through inefficient DNA repair, thereby contributing to the superior survival. Patients with stage III-IV CRC are commonly treated with oxaliplatin-containing chemotherapy, which in contrast to other platinum compounds does not kill cells through the DNA damage response [@bib0053]. Thus, HRD is not expected to be beneficial for treatment efficacy in this setting. However, these somewhat conflicting results reinforce the need for interpretation of genomic HRD scores according to cancer type. A recent study suggested that the phenotypic impact of *BRCA* mutations on mutational patterns and PARP inhibitor sensitivity is restricted to cancer types associated with BRCA-mediated heritable cancer risk (i.e. breast, ovary, pancreatic and prostate cancers) [@bib0054]. Thus, mutations in *BRCA1/2* and other genes related to HRD found in CRC may be biologically neutral passenger mutations with limited impact on phenotype and drug sensitivity. However, the exact impact of each gene on homologous recombination and/or PARP inhibitor sensitivity is likely very diverse, both with respect to character and magnitude. The association between defects in *ATM* and abrogated homologous recombination and sensitivity to PARP inhibition is well-characterized in various tumour types [@bib0011]. Our finding of SKCO1 cells with deleted *ATM* and *TP53* wild-type status to have clearly the strongest PARP inhibitor sensitivity *and* the highest HRD score among the sensitive cell lines provides multi-level support of *ATM* defects as a relevant predictive marker of PARP inhibition also in CRC.

In conclusion, we demonstrated activity of PARP inhibitors in a subset of CRC cell lines. The limited predictive value of existing HRD-related biomarkers suggested a need for development of novel stratified treatment strategies with respect to PARP inhibition in CRC, and this study points to wild-type TP53 function as a relevant starting point.

Appendix. Supplementary materials {#sec0028}
=================================

Image, application 1

Acknowledgements {#sec0023}
================

Not applicable.

Funding sources {#sec0024}
===============

This work was supported by the 10.13039/100008730Norwegian Cancer Society (project numbers 6824048-2016 and 182759-2016); the foundation \"10.13039/100007793Stiftelsen Kristian Gerhard Jebsen\"; the South-Eastern Norway Regional Health Authority (project number 2017102), and the 10.13039/501100005416Research Council of Norway (FRIPRO Toppforsk, project number 250993). The funders had no role in study design, data acquisition, analysis, interpretation, writing or submission of the manuscript.

Declaration of Interests {#sec0025}
========================

The authors declare no competing interests.

Authors\' contributions {#sec0026}
=======================

RAL and AS conceived the study. RAL, AS, MGG, AN, JB and JS designed the study. AN, KK, KCGB, PWE, IAE and JB acquired data. KCGB, PWE, AS, RAL, KK, BJ and JS analysed and/or interpreted data. JS and AS drafted the manuscript. All authors revised and approved the manuscript.

Supplementary material associated with this article can be found in the online version at <https://doi.org/10.1016/j.ebiom.2020.102923>.

[^1]: Shared first authorship

[^2]: Number of tumours with any non-silent mutation

[^3]: Nonsense and frameshift mutations

[^4]: Genes harbouring homozygous mutations, biallelic deletions or mutations in the single remaining allele included. 133 genes implicated in homologous recombination and/or PARP inhibitor sensitivity have been investigated.

[^5]: See Supplementary Table S7 for full list of mutations in relevant genes

[^6]: Gene expression-based signature of PARP inhibitor sensitivity

    HR: homologous recombination, n.a.; not available, mut; mutated, PARPi; PARP inhibitor wt; wild-type
